DLBS1033

Phase 3Small molecule

DDexa Medica Group

DLBS1033 is one of 53 small molecule programs targeting Safety and Efficacy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Safety and EfficacyCompleted

Diabetic PolyneuropathyNot yet recruiting

Safety and EfficacyPreclinical

Completed

Diabetic PolyneuropathyPhase 3

Not yet recruiting

Competition

Competitive Landscape

149 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

8 2

Opdivo

Bristol-Myers Squibb

Phase 3

7 3

Humira

Novartis

Phase 3

3 4

Avastin

Roche

Phase 3

3 5

BEYFORTUS

Sanofi

Phase 3

1 6

Neulasta

Amgen

Phase 3

1 7

Adriamycin

Pfizer

Phase 3

1 8

Oncovin

Eli Lilly

Phase 3

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

6 10

Rayos

RRoxane Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemic stroke4 trials

Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke

Completed·DDexa Medica Group·Phase 3·NCT01790997·126 enrolled

DLBS1033 for the Treatment of Acute Ischemic Stroke

Terminated·DDexa Medica Group·Phase 3·NCT02362984·9 enrolled

DLBS1033 for Acute Ischemic Stroke Patients

Terminated·DDexa Medica Group·Phase 2/3·NCT02133521·80 enrolled

Show 1 more trial

The Benefit of Add On DLBS1033 for Ischemic Stroke Patient

Unknown status·—·Phase 2/3·NCT04425590·180 enrolled

Type 2 Diabetes Mellitus1 trial

Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

Completed·DDexa Medica Group·Phase 4·NCT01865474·122 enrolled

Coronary Revascularization1 trial

DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

Withdrawn·DDexa Medica Group·Phase 2/3·NCT02146664

Peripheral Arterial Disease1 trial

DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease

Terminated·DDexa Medica Group·Phase 2/3·NCT02145988·11 enrolled

HAE1 trial

The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers

Completed·IIndonesia University·Phase 2·NCT01694537·21 enrolled

4 more indications

Safety and Efficacy1 trial

Safety and Efficacy of DLBS1033 in Healthy Subjects

Completed·DDexa Medica Group·N/A·NCT01378585·20 enrolled

Diabetic Polyneuropathy1 trial

The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy

Not yet recruiting·UUniversitas Sebelas Maret·Phase 2/3·NCT07475065·34 enrolled

Vertigo1 trial

Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

Completed·UUniversitas Sebelas Maret·Phase 4·NCT07075289·44 enrolled

Unspecified2 trials

Biological Half Life of DLBS1033 in Healthy Volunteers

Completed·IIndonesia University·Phase 1/2·NCT01905878·14 enrolled

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Terminated·DDexa Medica Group·Phase 2/3·NCT02976701·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for DLBS1033. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DLBS1033 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DLBS1033. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dexa Medica Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDexa Medica Group

DLBS1033

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemic stroke4 trials

Type 2 Diabetes Mellitus1 trial

Coronary Revascularization1 trial

Peripheral Arterial Disease1 trial

HAE1 trial

Safety and Efficacy1 trial

Diabetic Polyneuropathy1 trial

Vertigo1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News